UNSPSC 51361706: Butoctamide succinate

This classification denotes the succinate form of a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6MDC25LQSR. European Medicines Agency schedules Butoctamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06028MIG. Butoctamide generally arises in the molecular formula C12H25NO2.

UNSPSC 51361706 Butoctamide succinate is a Commodity code, but the recent state and local opportunities tagged under it do not reflect procurement of this specific pharmaceutical compound. Instead, the tagged solicitations capture a broader set of state and local health and human services pharmaceutical purchasing — including naloxone distribution, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical supply agreements. The actual buying activity under this code at the state and local level spans emergency-response medications (such as naloxone for opioid overdose reversal), prescription fulfillment through alternative distribution channels, and generic pharmaceutical commodity supply to support public health facilities and employee health plans. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas Health and Human Services Commission), and multi-state cooperative purchasing consortiums (the Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, with participating states including Minnesota and Oregon).

The code shows recent activity concentrated in Florida and Texas, with multi-state procurement coordination through the Upper Midwest. Representative recent opportunities include Seminole County's IFB60459723LAS, posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023 (IFB notice type); Texas HHS Commission's RFI HHS0017013, issued April 3, 2026, soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish alternative prescription fulfillment pathways outside traditional pharmacy benefit manager arrangements; and MMCAP's S1070000015802, an RFP posted January 20, 2026 with a response deadline of March 26, 2026, establishing multi-state contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers to participating public health facilities. The MMCAP solicitation emphasizes price competitiveness (weighted 75 percent), cGMP and Drug Supply Chain Security Act compliance, and contractual relationships with specified wholesalers.